Catalog Number : 500-P18
Produced from sera of rabbits pre-immunized with highly pure recombinant Human FGF-basic. Anti-Human FGF-basic specific antibody was purified by affinity chromatography employing immobilized Human FGF-basic matrix.
|Application:||ELISA, Western Blot, Neutralization, Immunohistochemistry|
Anti-Human FGF-basic (BioGems Catalog #100-18B)
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentrations are 0.25 μg/ml-0.5 μg/ml for two hours at room temperature. An HRP-labeled polymer detection system was used with DAB chromogen. Heat induced antigen retrieval was performed with a pH 6.0 Sodium Citrate buffer. Optimal concentrations and conditions may vary.
To yield one-half maximal inhibition [ND50] of the biological activity of Human FGF-basic (0.3 ng/ml), a concentration of 0.25 - 0.40 µg/ml of this antibody is required.
To detect Human FGF-basic by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human FGF-basic (60-133BT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human FGF-basic.
To detect Human FGF-basic by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant Human FGF-basic is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.